Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Other neoplasm 1

Conditions

Neurofibromatosis 1 3Breast Neoplasms 3Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Prostatic Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Noonan Syndrome 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Learning Disabilities 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Dyslexia 1Cognition Disorders 1Carcinoma, Ovarian Epithelial 1Carcinoma 1Breast Carcinoma In Situ 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Lovastatin × Clear all
NCT00462280 2014-10-31

Lovastatin in Treating Patients At High Risk of Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
80 enrolled 35 charts
DermatologicOther neoplasm

Melanoma, Precancerous Conditions

NCT00963664 2009-09-09

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

NeoPlas Innovation

Phase 2 Withdrawn
250 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡